A biotechnology firm, 9 Meters Biopharma (NMTR), focuses on patients with rare diseases and unmet needs. The company’s portfolio contains drug candidates with short bowel syndrome (SBS) and celiac disease.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The Company with a Market Cap of 217.64 M was up 27.53% to 1.0700 at yesterday’s close. It stayed up even expanded 23.36% to 1.32 in the extended session. During the last 52-weeks’ time,the Company stock price ranged from $0.3700 to $1.2200. In the previous trading session,17,412,006 shares of NMTR changed hands compared to its average volume of 3,740,066.
There is no update available or revealed by the company itself in the last 24 hours. However, developments in the previous couple of months have put the stock in positive territory.
• On December 21, 2020, an agreement was revealed between the 9 Meters Biopharma and the European Biomedical Research Institute of Salerno (EBRIS), led to the advancement of a study on larazotide injections in healthy volunteers to evaluate larazotide safety and tolerability in lung tissue.
• On December 16, 2020, the company announced the closing of its previously announced underwritten public offering of 53,076,924 shares of its common stock at a price to the public of $0.65.
• On December 9, 2020,NMTR said that a proprietary long-acting agonist of the GLP-2 receptor had been granted orphan drug designation by the Food and Drug Administration (FDA) as a preventative of acute graft versus host disease.